Skin Elements (ASX:SKN) - Executive Chairman, Peter Malone
Executive Chairman, Peter Malone
Source: Business News
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Skin Elements (SKN) has secured $10.5 million through an underwriting agreement with State Securities
  • The funds will support Skin Elements’ international rollout of its Invisi-Shield natural hand sanitiser
  • This range was launched late last month after two years of research and testing
  • In addition, Skin Elements will use the money to develop and promote its natural skincare products
  • Skin Elements is up 26 per cent and shares are trading for 9.7 cents each

Skin Elements (SKN) has secured $10.5 million through an underwriting agreement with State Securities.

This agreement will guarantee that Skin Elements receives $10.5 million from the exercise of the SKN options, before costs.

Under the agreement, State Securities will underwrite the exercise of 95,488,641 quoted options exercisable at 10 cents each on or before December 31 2020, and 36,493,274 unquoted options exercisable at 0.3 cents on or before December 31 2020.

State Securities will receive a six per cent underwriting fee of the total raised amount.

These funds will support Skin Elements’ international rollout of its recently launched Invisi-Shield natural hand sanitiser product range. The money will also aid in the ongoing expansion of production and marketing of Skin’s natural skincare products.

The Invisi-Shield hand sanitiser range was launched in late March after a two year phase of research, testing and development.

Furthermore, Skin Elements teamed up with Holista Colltech (HCT), who’s also at the forefront of hand sanitiser production, to jointly produce a natural, alcohol-free sanitiser. The agreement was recently announced on April 3.

Skin Elements is up 26 per cent and shares are trading for 9.7 cents each at 12:15 pm AEST.

SKN by the numbers
More From The Market Herald
The Market Herald Video

" Cynata Therapeutics (ASX:CYP) to conclude MEND trial following strategic review

Cynata Therapeutics (ASX:CYP) has completed a strategic review of its clinical development pipeline to maximise commercial…
The Market Herald Video

" AVITA Medical (ASX:AVH) reports positive results from soft tissue trial

AVITA Medical (ASX:AVH) reports positive top line results for its RECELL trial in patients with soft-tissue…
Paradigm Biopharmaceuticals (ASX:PAR) - CEO, Marco Polizzi

" Paradigm Biopharmaceuticals (ASX:PAR) enters trading halt amid cap raise

Paradigm Biopharmaceuticals (ASX:PAR) has entered into a trading halt ahead of a capital raise.
HITIQ (ASX:HIQ) - CEO, Mike Vegar

" HITIQ (ASX:HIQ) secures third Australian innovation patent

HITIQ (ASX:HIQ) has secured a third Australian innovation patent related to its virtual reality (VR) concussion…